JP2024534116A - 免疫抑制性ｂ細胞と関連付けられる癌を処置する方法 - Google Patents

免疫抑制性ｂ細胞と関連付けられる癌を処置する方法 Download PDF

Info

Publication number
JP2024534116A
JP2024534116A JP2024511969A JP2024511969A JP2024534116A JP 2024534116 A JP2024534116 A JP 2024534116A JP 2024511969 A JP2024511969 A JP 2024511969A JP 2024511969 A JP2024511969 A JP 2024511969A JP 2024534116 A JP2024534116 A JP 2024534116A
Authority
JP
Japan
Prior art keywords
heavy chain
region
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024511969A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534116A5 (cg-RX-API-DMAC10.html
Inventor
プレスタ，レオナルド
トゥーメ，ポール
ロンバーグ，ニルス
ドゥラマド，オマル
Original Assignee
バイオグラフ ５５，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオグラフ ５５，インク． filed Critical バイオグラフ ５５，インク．
Publication of JP2024534116A publication Critical patent/JP2024534116A/ja
Publication of JP2024534116A5 publication Critical patent/JP2024534116A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024511969A 2021-08-25 2022-08-24 免疫抑制性ｂ細胞と関連付けられる癌を処置する方法 Pending JP2024534116A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163236953P 2021-08-25 2021-08-25
US63/236,953 2021-08-25
PCT/US2022/041395 WO2023028159A1 (en) 2021-08-25 2022-08-24 Methods of treating cancers associated with immunosuppressive b cells

Publications (2)

Publication Number Publication Date
JP2024534116A true JP2024534116A (ja) 2024-09-18
JP2024534116A5 JP2024534116A5 (cg-RX-API-DMAC10.html) 2025-08-29

Family

ID=85322012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024511969A Pending JP2024534116A (ja) 2021-08-25 2022-08-24 免疫抑制性ｂ細胞と関連付けられる癌を処置する方法

Country Status (9)

Country Link
US (1) US20240392000A1 (cg-RX-API-DMAC10.html)
EP (1) EP4392062A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024534116A (cg-RX-API-DMAC10.html)
KR (1) KR20240055016A (cg-RX-API-DMAC10.html)
CN (1) CN118139639A (cg-RX-API-DMAC10.html)
AU (1) AU2022332971A1 (cg-RX-API-DMAC10.html)
CA (1) CA3229824A1 (cg-RX-API-DMAC10.html)
IL (1) IL310941A (cg-RX-API-DMAC10.html)
WO (1) WO2023028159A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021173844A1 (en) * 2020-02-26 2021-09-02 Biograph 55, Inc. C19 c38 bispecific antibodies
TW202440636A (zh) * 2023-03-21 2024-10-16 美商傳記５５有限公司 Ｃｄ１９／ｃｄ３８多特異性抗體
WO2026064774A1 (en) * 2024-09-23 2026-03-26 Biograph 55, Inc. Cd19/cd38 multispecific antibodies for immune checkpoint inhibitor combination therapies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3587448B1 (en) * 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
EP3313441B1 (en) * 2015-06-24 2024-02-21 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
WO2021173844A1 (en) * 2020-02-26 2021-09-02 Biograph 55, Inc. C19 c38 bispecific antibodies

Also Published As

Publication number Publication date
EP4392062A1 (en) 2024-07-03
AU2022332971A1 (en) 2024-03-21
CA3229824A1 (en) 2023-03-02
US20240392000A1 (en) 2024-11-28
KR20240055016A (ko) 2024-04-26
WO2023028159A1 (en) 2023-03-02
CN118139639A (zh) 2024-06-04
IL310941A (en) 2024-04-01
EP4392062A4 (en) 2025-11-19

Similar Documents

Publication Publication Date Title
AU2020202792B9 (en) Humanized or chimeric CD3 antibodies
JP7811176B2 (ja) Ｃ１９ ｃ３８二特異性抗体
US20240392000A1 (en) Methods of treating cancers associated with immunosuppressive b cells
US12173081B2 (en) CD19/CD38 multispecific antibodies
US20240352156A1 (en) Antibodies targeting immunosuppressive b cells
TW202317612A (zh) 用於治療癌症的ｃｔｌａ４及ｐｄ１／ｐｄｌ１抗體之組合
JP7811028B2 (ja) ヒトｃｘｃｌ１６抗体およびその使用
CN115698066A (zh) 抗cd47抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250821